Weiss Matthew J, Kim Yuhree, Ejaz Aslam, Spolverato Gaya, Haut Elliott R, Hirose Kenzo, Wolfgang Christopher L, Choti Michael A, Pawlik Timothy M
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
HPB (Oxford). 2014 Oct;16(10):892-8. doi: 10.1111/hpb.12278. Epub 2014 May 28.
No consensus exists for post-hepatectomy venous thromboembolic (VTE) prophylaxis. Factors impacting VTE prophylaxis patterns among hepato-pancreato-biliary (HPB) surgeons were defined.
Surgeons were invited to complete a web-based survey on VTE prophylaxis. The impact of physician and clinical factors was analysed.
Two hundred responses were received. Most respondents were male (91%) and practiced at academic centres (88%) in the United States (80%). Surgical training varied: HPB (24%), transplantation (24%), surgical oncology (34%), HPB/transplantation (13%), or no specialty (5%). Respondents estimated VTE risk was higher after major (6%) versus minor (3%) resections. Although 98% use VTE prophylaxis, there was considerable variability: sequential compression devices (SCD) (91%), unfractionated heparin Q12h (31%) and Q8h (32%), and low-molecular weight heparin (39%). While 88% noted VTE prophylaxis was not impacted by operative indication, 16% stated major resections reduced their VTE prophylaxis. Factors associated with the decreased use of pharmacologic prophylaxis included: elevated international normalized ratio (INR) (74%), thrombocytopaenia (63%), liver insufficiency (58%), large EBL (46%) and complications (8%). Forty-seven per cent of respondents wait until ≥post-operative day 1 (POD1) and 35% hold pharmacologic VTE prophylaxis until no signs of coagulopathy. A minority (14%) discharge patients on pharmacologic prophylaxis. While 81% have institutional VTE guidelines, 79% believe hepatectomy-specific guidelines would be helpful.
There is considerable variation regarding VTE prophylaxis among liver surgeons. While most HPB surgeons employ VTE prophylaxis, the methods, timing and purported contraindications differ significantly.
肝切除术后静脉血栓栓塞(VTE)预防尚无共识。确定了影响肝胰胆(HPB)外科医生VTE预防模式的因素。
邀请外科医生完成一项关于VTE预防的网络调查。分析了医生因素和临床因素的影响。
共收到200份回复。大多数受访者为男性(91%),在美国学术中心执业(88%)(80%)。外科培训背景各异:HPB(24%)、移植(24%)、外科肿瘤学(34%)、HPB/移植(13%)或无特定专业(5%)。受访者估计,大手术(6%)后VTE风险高于小手术(3%)后。虽然98%的人使用VTE预防措施,但存在很大差异:序贯加压装置(SCD)(91%)、普通肝素每12小时一次(31%)和每8小时一次(32%)、低分子肝素(39%)。虽然88%的人指出VTE预防不受手术指征影响,但16%的人表示大手术会减少他们的VTE预防措施。与减少药物预防使用相关的因素包括:国际标准化比值(INR)升高(74%)、血小板减少(63%)、肝功能不全(58%)、大量失血(46%)和并发症(8%)。47%的受访者等到术后第1天及以后(POD1),35%的人在没有凝血异常迹象之前停用药物VTE预防措施。少数人(14%)让患者出院时继续接受药物预防。虽然81%的人有机构VTE指南,但79%的人认为肝切除特异性指南会有所帮助。
肝脏外科医生在VTE预防方面存在很大差异。虽然大多数HPB外科医生采用VTE预防措施,但方法、时机和所谓的禁忌证差异很大。